Rechallenge with encorafenib and cetuximab for BRAF-mutated colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the targeted therapy combination encorafenib (a BRAF inhibitor) plus cetuximab (an anti-EGFR antibody) again can help people whose metastatic colorectal cancer has a BRAF V600E mutation and whose disease progressed after a prior response to a similar treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer with a confirmed BRAF V600E mutation.
- You have been treated with at least 2 prior chemotherapy regimens for metastatic disease.
- You previously received a BRAF inhibitor plus an anti-EGFR drug combination for at least 4 months and had stable disease for more than 6 months or a partial or complete response.
- At least 4 months have passed since your last BRAF inhibitor treatment.
- Your cancer has grown during or within 6 months of your last chemotherapy regimen.
- You are age 18 or older, and your daily activities are not limited (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
This trial tests a combination of three drugs (cetuximab, irinotecan, and envafolimab) as a ‘rechallenge’ – meaning if you had good results with cetuximab or irinotecan before, trying them again with a new drug might help shrink or control your cancer.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.